

## GHANA PENTAVALENT VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Ghana			
<b>2. Grant Number:</b> 0715-GHA-04c-X			
<b>3. Date of Decision Letter:</b> 12 December 2014.			
<b>4. Date of the Partnership Framework Agreement:</b> 11 July 2014			
<b>5. Programme Title:</b> NVS, Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
<b>8. Programme Duration<sup>1</sup>:</b> 2002 - 2015			
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>			
	2002-2014	2015	Total <sup>2</sup>
Programme Budget (US\$)	US\$85,209,783 <sup>3</sup>	US\$5,964,000	US\$91,173,783
<b>10. Vaccine Introduction Grant:</b> Not applicable.			
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b> The Annual Amount for 2015 has been amended.			
Type of supplies to be purchased with Gavi funds in each year	2002-2014	2015	
Number of Pentavalent vaccines doses		3,536,000	
Number of AD syringes		3,204,600	
Number of re-constitution syringes			
Number of safety boxes		35,275	
Annual Amounts (US\$)	US\$85,209,783 <sup>5</sup>	US\$5,964,000	

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>12. Procurement agency:</b> UNICEF.													
<b>13. Self-procurement:</b> Not applicable.													
<p><b>14. Co-financing obligations:</b> Reference code: 0715-GHA-04c-X-C. According to the Co-Financing Policy, the Country falls within the Graduating group as of 1 January 2015. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2015</td> </tr> <tr> <td>Number of vaccine doses</td> <td>765,500</td> </tr> <tr> <td>Number of AD syringes</td> <td>693,400</td> </tr> <tr> <td>Number of safety boxes</td> <td>7,650</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$1,201,977</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$1,290,500</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	765,500	Number of AD syringes	693,400	Number of safety boxes	7,650	Value of vaccine doses (US\$)	US\$1,201,977	Total Co-Financing Payments (US\$) (including freight)	US\$1,290,500
Type of supplies to be purchased with Country funds in each year	2015												
Number of vaccine doses	765,500												
Number of AD syringes	693,400												
Number of safety boxes	7,650												
Value of vaccine doses (US\$)	US\$1,201,977												
Total Co-Financing Payments (US\$) (including freight)	US\$1,290,500												
<b>15. Operational support for campaigns:</b> Not applicable													
<b>16. Additional documents to be delivered for future disbursements:</b>													
Reports, documents and other deliverables	Due dates												
Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.												
<p><b>17. Financial Clarifications:</b> The Country shall provide the following clarifications to Gavi*: Not applicable.</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>													
<b>18. Other conditions:</b> Not applicable.													

On behalf of the GAVI Alliance



Hind Khatib-Othman  
Managing Director, Country Programmes

12 December 2014

**GHANA MEASLES SECOND DOSE VACCINE SUPPORT**  
This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Ghana				
<b>2. Grant Number:</b> 1516-GHA-09a-X				
<b>3. Date of Decision Letter:</b> 12 December 2014				
<b>4. Date of the Partnership Framework Agreement:</b> 11 July 2014				
<b>5. Programme Title:</b> NVS, Measles second dose Routine				
<b>6. Vaccine type:</b> Measles				
<b>7. Requested product presentation and formulation of vaccine:</b> Measles, 10 dose(s) per vial, LYOPHILISED				
<b>8. Programme Duration<sup>1</sup>:</b> 2012 - 2016				
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>				
	2012-2014	2015	2016	Total <sup>2</sup>
Programme Budget (US\$)	US\$1,278,548 <sup>3</sup>	US\$139,500	US\$452,500	US\$1,870,548
<b>10. Vaccine Introduction Grant:</b> Not applicable.				
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b> The Annual Amount for 2015 has been amended.				
Type of supplies to be purchased with Gavi funds in each year	2012-2014	2015		
Number of Measles vaccines doses		279,100		
Number of AD syringes		993,900		
Number of re-constitution syringes		30,700		
Number of safety boxes		11,275		
Annual Amounts (US\$)	US\$1,278,548 <sup>5</sup>	US\$139,500		

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>12. Procurement agency:</b> UNICEF.		
<b>13. Self-procurement:</b> Not applicable.		
<b>14. Co-financing obligations:</b> Reference code: According to the Co-Financing Policy, the Country falls within the Graduating group as of 1 January 2015.  Co-financing is not applicable for measles second dose support.		
<b>15. Operational support for campaigns:</b> Not applicable		
	2015	2016
Grant amount (US\$)	US\$	US\$
<b>16. Additional documents to be delivered for future disbursements:</b>		
Reports, documents and other deliverables	Due dates	
Annual Progress Report or its equivalent	As agreed with the Gavi Secretariat	
<b>17. Financial Clarifications:</b> The Country shall provide the following clarifications to Gavi*: Not applicable.  <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>		
<b>18. Other conditions:</b> Not applicable		

On behalf of the GAVI Alliance



Hind Khatib-Othman  
Managing Director, Country Programmes

12 December 2014

## GHANA PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Ghana					
<b>2. Grant Number:</b> 1517-GHA-12c-X					
<b>3. Date of Decision Letter:</b> 12 December 2014					
<b>4. Date of the Partnership Framework Agreement:</b> 11 July 2014					
<b>5. Programme Title:</b> NVS, Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID					
<b>8. Programme Duration<sup>1</sup>:</b> 2012 - 2017					
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>					
	2012-2014	2015	2016	2017	Total <sup>2</sup>
Programme Budget (US\$)	US\$55,208,837 <sup>3</sup>	US\$9,899,000	US\$8,693,500	US\$9,812,000	US\$83,613,337
<b>10. Vaccine Introduction Grant:</b> Not applicable.					
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup> The Annual Amount for 2015 has been amended.</b>					
Type of supplies to be purchased with Gavi funds in each year	2012-2014	2015			
Number of Pneumococcal vaccines doses		2,336,400			
Number of AD syringes		2,415,100			
Number of safety boxes		26,600			
Annual Amounts (US\$)	US\$55,208,837 <sup>5</sup>	US\$9,899,000			
<b>12. Procurement agency:</b> UNICEF.					

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.



<b>13. Self-procurement:</b> Not applicable.																															
<p><b>14. Co-financing obligations:</b> Reference code: 1517-GHA-12c-X-C. According to the Co-Financing Policy, the Country falls within the Graduating group as of 1 January 2015.</p> <p>The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2015</th> <th>2016</th> <th>2017</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>210,600</td> <td>779,400</td> <td>1,362,600</td> </tr> <tr> <td>Number of AD syringes</td> <td>217,500</td> <td></td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>2,400</td> <td></td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$709,874</td> <td></td> <td></td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$764,500</td> <td>US\$2,845,000</td> <td>US\$4,862,500</td> </tr> </tbody> </table>				Type of supplies to be purchased with Country funds in each year	2015	2016	2017	Number of vaccine doses	210,600	779,400	1,362,600	Number of AD syringes	217,500			Number of re-constitution syringes				Number of safety boxes	2,400			Value of vaccine doses (US\$)	US\$709,874			Total Co-Financing Payments (US\$) (including freight)	US\$764,500	US\$2,845,000	US\$4,862,500
Type of supplies to be purchased with Country funds in each year	2015	2016	2017																												
Number of vaccine doses	210,600	779,400	1,362,600																												
Number of AD syringes	217,500																														
Number of re-constitution syringes																															
Number of safety boxes	2,400																														
Value of vaccine doses (US\$)	US\$709,874																														
Total Co-Financing Payments (US\$) (including freight)	US\$764,500	US\$2,845,000	US\$4,862,500																												
<p><b>15. Operational support for campaigns:</b> Not applicable</p> <table border="1"> <thead> <tr> <th></th> <th>2015</th> <th>2016</th> </tr> </thead> <tbody> <tr> <td>Grant amount (US\$)</td> <td>US\$</td> <td>US\$</td> </tr> </tbody> </table>					2015	2016	Grant amount (US\$)	US\$	US\$																						
	2015	2016																													
Grant amount (US\$)	US\$	US\$																													
<p><b>16. Additional documents to be delivered for future disbursements:</b></p> <table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or its equivalent.</td> <td>At a date agreed with Gavi Secretariat.</td> </tr> </tbody> </table>				Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.																								
Reports, documents and other deliverables	Due dates																														
Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.																														
<p><b>17. Financial Clarifications:</b> The Country shall provide the following clarifications to Gavi*: Not applicable.</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>																															
<b>18. Other conditions:</b> Not applicable.																															

On behalf of the GAVI Alliance



Hind Khatib-Othman  
Managing Director, Country Programmes

12 December 2014

## GHANA ROTAVIRUS VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Ghana					
<b>2. Grant Number:</b> 1517-GHA-13b-X					
<b>3. Date of Decision Letter:</b> 12 December 2014					
<b>4. Date of the Partnership Framework Agreement:</b> 11 July 2014					
<b>5. Programme Title:</b> NVS, Rotavirus Routine					
<b>6. Vaccine type:</b> Rotavirus					
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule					
<b>8. Programme Duration<sup>1</sup>:</b> 2012 - 2017					
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>					
	2012-2014	2015	2016	2017	Total <sup>2</sup>
Programme Budget (US\$)	US\$13,642,679 <sup>3</sup>	US\$3,648,500	US\$4,119,500	US\$3,231,500	US\$24,642,179
<b>10. Vaccine Introduction Grant:</b> Not applicable.					
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b> The Annual Amount for 2015 has been amended.					
Type of supplies to be purchased with Gavi funds in each year		2012-2014	2015		
Number of Rotavirus vaccines doses			1,369,500		
Annual Amounts (US\$)		US\$13,642,679 <sup>5</sup>	US\$3,648,500		
<b>12. Procurement agency:</b> UNICEF.					
<b>13. Self-procurement:</b> Not applicable.					

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations: Reference code: 1517-GHA-13b-X-C.** According to the Co-Financing Policy, the Country falls within the Graduating group as of 1 January 2015. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015	2016	2017
Number of vaccine doses	175,500	591,000	987,000
Value of vaccine doses (US\$)	US\$446,084		
Total Co-Financing Payments (US\$) (including freight)	US\$463,500	US\$1,602,000	US\$2,677,500

**15. Operational support for campaigns: Not applicable**

	2015	2016
Grant amount (US\$)	US\$	US\$

**16. Additional documents to be delivered for future disbursements:**

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent.	As agreed with Gavi Secretariat.

**17. Financial Clarifications:** The Country shall provide the following clarifications to Gavi\*: Not applicable.

*\*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

**18. Other conditions:** Not applicable.

**On behalf of the GAVI Alliance**



Hind Khatib-Othman  
Managing Director, Country Programmes

12 December 2014



## GHANA YELLOW FEVER VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

<b>1.</b>	<b>Country:</b> Ghana			
<b>2.</b>	<b>Grant Number:</b> 0715-GHA-06b-X			
<b>3.</b>	Date of Decision Letter: 12 December 2014			
<b>4.</b>	Date of the Partnership Framework Agreement: 11 July 2014			
<b>5.</b>	<b>Programme Title:</b> NVS, Yellow Fever Routine			
<b>6.</b>	<b>Vaccine type:</b> Yellow Fever			
<b>7.</b>	Requested product presentation and formulation of vaccine: Yellow Fever, 10 dose(s) per vial, LYOPHILISED			
<b>8.</b>	Programme Duration <sup>1</sup> : 2001 - 2015			
<b>9.</b>	Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
		2001-2014	2015	Total <sup>2</sup>
	Programme Budget (US\$)	US\$8,730,985 <sup>3</sup>	US\$785,000	US\$9,515,985
<b>10.</b>	<b>Vaccine Introduction Grant:</b> Not applicable.			
<b>11.</b>	<b>Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):</b> <sup>4</sup> The Annual Amount for 2015 has been amended.			
	Type of supplies to be purchased with Gavi funds in each year	2001-2014	2015	
	Number of Yellow Fever vaccines doses		699,400	
	Number of AD syringes		604,800	
	Number of re-constitution syringes		77,000	
	Number of safety boxes		7,500	
	Annual Amounts (US\$)	US\$8,730,985 <sup>5</sup>	US\$785,000	

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>12. Procurement agency:</b> UNICEF.															
<b>13. Self-procurement:</b> Not applicable.															
<p><b>14. Co-financing obligations:</b> Reference code: 0715-GHA-06b-X-C. According to the Co-Financing Policy, the Country falls within the Graduating group as of 1 January 2015.</p> <p>The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>468,600</td> </tr> <tr> <td>Number of AD syringes</td> <td>405,200</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>51,600</td> </tr> <tr> <td>Number of safety boxes</td> <td>5,025</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$468,886</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$526,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	468,600	Number of AD syringes	405,200	Number of re-constitution syringes	51,600	Number of safety boxes	5,025	Value of vaccine doses (US\$)	US\$468,886	Total Co-Financing Payments (US\$) (including freight)	US\$526,000
Type of supplies to be purchased with Country funds in each year	2015														
Number of vaccine doses	468,600														
Number of AD syringes	405,200														
Number of re-constitution syringes	51,600														
Number of safety boxes	5,025														
Value of vaccine doses (US\$)	US\$468,886														
Total Co-Financing Payments (US\$) (including freight)	US\$526,000														
<b>15. Operational support for campaigns:</b> Not applicable															
<b>16. Additional documents to be delivered for future disbursements:</b> Not applicable															
<table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or its equivalent.</td> <td>At a date agreed with Gavi Secretariat.</td> </tr> </tbody> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.										
Reports, documents and other deliverables	Due dates														
Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.														
<p><b>17. Financial Clarifications:</b> The Country shall provide the following clarifications to Gavi*: Not applicable.</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>															
<p><b>Other conditions:</b> There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.</p>															

On behalf of the GAVI Alliance



Hind Khatib-Othman  
Managing Director, Country Programmes

12 December 2014